|
CN1909905A
|
|
Method for treating erectile dysfunction
|
|
IL165449D0
|
|
Aminoalcohol derivatives and pharmaceutical compositions containing the same
|
|
US2005245540A1
|
|
New methods
|
|
TW200528440A
|
|
2-cyanopyrrolidinecarboxamide compound
|
|
WO2005038443A1
|
|
Different-kind-of-object detector employing plane spectrometer
|
|
JP2005120083A
|
|
Antitumor agent
|
|
US2006063794A1
|
|
Method of attenuating graft rejection
|
|
US2005025769A1
|
|
Method of suppressing ongoing acute allograft rejection
|
|
JP2005089450A
|
|
Prophylactic or therapeutic agent for infectious disease caused by rs virus
|
|
WO2005003111A1
|
|
Preventive or remedy for viral conjunctivitis
|
|
JP2004285075A
|
|
Method for improving elution property of hardly dispersible medicine
|
|
JP2004352712A
|
|
Agent for preventing or treating influenza
|
|
US2005233330A1
|
|
Method for identifying myelodysplastic syndrome-specific genes
|
|
JP2005295948A
|
|
Method for identifying myelodysplastic syndrome-specific gene
|
|
WO2004093910A1
|
|
REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPARδ AGONIST
|
|
JP2005297321A
|
|
Document file
|
|
WO2004096289A1
|
|
Gene introduction efficiency enhancer
|
|
WO2004089939A1
|
|
Condensed furan derivatives as adenosine antagonists
|
|
GB0402269D0
|
|
Method of screening for new drugs
|
|
CN1761655A
|
|
Thiazole derivatives and their use as VAP-1 inhibitors
|
